Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Bioorg Med Chem Lett ; 30(23): 127626, 2020 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-33096161

RESUMEN

Human tissue kallikreins (KLKs) constitute a family of 15 serine proteases that are distributed in various tissues and implicated in several pathological disorders. KLK7 is an unusual serine protease that presents both trypsin-like and chymotrypsin-like specificity and appears to be upregulated in pathologies that are related to skin desquamation processes, such as atopic dermatitis, psoriasis and Netherton syndrome. In recent years, various groups have worked to develop specific inhibitors for this enzyme, as KLK7 represents a potential target for new therapeutic procedures for diseases related to skin desquamation processes. In this work, we selected nine different single-chain variable fragment antibodies (scFv) from a human naïve phage display library and characterized their inhibitory activities against KLK7. The scFv with the lowest IC50 against KLK7 was affinity maturated, which resulted in the generation of four new scFv-specific antibodies for the target protease. These new antibodies were expressed in the scFv-Fc format in HEK293-6E cells, and the characterization of their inhibitory activities against KLK7 showed that three of them presented IC50 values lower than that of the original antibody. The cytotoxicity analysis of these recombinant antibodies demonstrated that they can be safely used in a cellular model. In conclusion, our research showed that in our case, a phage-display methodology in combination with enzymology assays can be a very suitable tool for the development of inhibitors for KLKs, suggesting a new strategy to identify therapeutic protease inhibitors for diseases related to uncontrolled kallikrein activity.


Asunto(s)
Calicreínas/antagonistas & inhibidores , Proteínas Recombinantes/inmunología , Inhibidores de Serina Proteinasa/inmunología , Anticuerpos de Cadena Única/inmunología , Animales , Chlorocebus aethiops , Células HEK293 , Humanos , Calicreínas/inmunología , Proteínas Recombinantes/toxicidad , Inhibidores de Serina Proteinasa/toxicidad , Anticuerpos de Cadena Única/toxicidad , Enfermedades de la Piel/terapia , Células Vero
2.
J Chem Inf Model ; 60(2): 731-737, 2020 02 24.
Artículo en Inglés | MEDLINE | ID: mdl-31850756

RESUMEN

The NS2B-NS3 protease has been identified as an attractive target for drug development against Zika virus (ZIKV) and combined drug repurposing and structure-based virtual screening has improved the development of antiviral drugs. In this study, we performed a structure-based virtual screening of 1861 Food and Administration (FDA) approved drugs available in DrugBank by the selection and docking validation of crystal structure of ZIKV NS2B-NS3 protease (PDB ID 5H4I ) using Glide and DOCK 6 software. The antihistaminic chlorcyclizine (Grid score -24.8 kcal/mol) exhibited the most promising interaction with NS2B-NS3 protease in comparison to crystallography ligand (Grid score -15.6 kcal/mol) by interaction to Tyr161 by hydrophobic interactions in the binding site of NS2B-NS3 which is recognized as an important amino acid in substrate molecular recognition. Cytotoxicity and global antiviral activity assay in Vero cells by MTT method showed that chlorcyclizine reduced the ZIKV induced cytopathic effect (EC50 of 69.0 ± 7.3 µM and SI = 1.9), and explicit molecular dynamics simulations implemented on a NAMD program indicated great stability of chlorcyclizine in protease binding site, suggesting the repurposing of chlorcyclizine as a promising finding in anti-ZIKV drug development.


Asunto(s)
Reposicionamiento de Medicamentos , Simulación de Dinámica Molecular , Inhibidores de Serina Proteinasa/química , Inhibidores de Serina Proteinasa/farmacología , Proteínas Virales/antagonistas & inhibidores , Virus Zika/enzimología , Animales , Chlorocebus aethiops , Conformación Proteica , Serina Endopeptidasas/química , Inhibidores de Serina Proteinasa/toxicidad , Células Vero , Proteínas Virales/química
3.
Artículo en Inglés | MEDLINE | ID: mdl-20692365

RESUMEN

Plants synthesize a variety of molecules to defend themselves against an attack by insects. Talisin is a reserve protein from Talisia esculenta seeds, the first to be characterized from the family Sapindaceae. In this study, the insecticidal activity of Talisin was tested by incorporating the reserve protein into an artificial diet fed to the velvetbean caterpillar Anticarsia gemmatalis, the major pest of soybean crops in Brazil. At 1.5% (w/w) of the dietary protein, Talisin affected larval growth, pupal weight, development and mortality, adult fertility and longevity, and produced malformations in pupae and adult insects. Talisin inhibited the trypsin-like activity of larval midgut homogenates. The trypsin activity in Talisin-fed larvae was sensitive to Talisin, indicating that no novel protease-resistant to Talisin was induced in Talisin-fed larvae. Affinity chromatography showed that Talisin bound to midgut proteinases of the insect A. gemmatalis, but was resistant to enzymatic digestion by these larval proteinases. The transformation of genes coding for this reserve protein could be useful for developing insect resistant crops.


Asunto(s)
Insecticidas , Mariposas Nocturnas , Proteínas de Plantas/toxicidad , Sapindaceae/metabolismo , Animales , Crecimiento y Desarrollo/efectos de los fármacos , Insecticidas/metabolismo , Larva/efectos de los fármacos , Larva/enzimología , Larva/crecimiento & desarrollo , Mariposas Nocturnas/enzimología , Mariposas Nocturnas/crecimiento & desarrollo , Proteínas de Plantas/metabolismo , Receptores de Superficie Celular/metabolismo , Inhibidores de Serina Proteinasa/metabolismo , Inhibidores de Serina Proteinasa/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA